SARS-CoV-2 peptide pools: PepMix

The PepMix™ range of peptide pools from JPT feature SARS-CoV-2 antigens and frequent mutations to enable in vitro stimulation of CD4+ and CD8+ T-cells for the measurement of T-cell response to specific SARS-CoV-2 antigens. These PepMixes contain overlapping peptide pools representing the Spike protein and corresponding receptor-binding domain (RBD) of the new B.1.1.7 SARS-CoV-2 variant, first reported in the UK.

Benefits of using the PepMix SARS-CoV-2 peptide pool
• Spike protein and RBD domain of B.1.1.7 variant represented
• Simultaneous CD4 and CD8 response detection in a single sample 
• Better or equivalent T-cell response stimulation compared to whole protein antigens
• Improved and easier T-cell response detection in stored blood and PBMCs compared to whole protein antigens
• Reliable quality control and quality assurance
• High batch-to-batch reproducibility
• Prolonged shelf life when stored freeze-dried
• Pooled and aliquoted according to ISO 9001:2008 and GCLP regulations

PepMix SARS-CoV-2 peptide pools applications
• SARS-CoV-2 clinical trial immune monitoring
• SARS-CoV-2 correlation of cellular and humoral immune responses
• SARS-CoV-2 evaluation of cross reactivities
• SARS-CoV-2 vaccine target identification
• SARS-CoV-2 blood and sero test development

PepMix SARS-CoV-2 peptide pools citations